Case Report

Hepatocellular Carcinoma in a Patient with Human Immunodeficiency Virus and Hepatitis B Virus Coinfection: An Emerging Problem?

Authors: LCDR Chris B. Hyun, MC, USNR, CDR Walter J. Coyle, MC, USN

Abstract

Infections with hepatitis B virus (HBV) and human immunodeficiency virus (HIV) have similar risk factors and routes of transmission. It is estimated that 64 to 84% of HIV-infected individuals have positive markers for anti-HBc antibodies, with the chronic HBV infection rate approaching 16%. There is, however, a paucity of information on HBV/HIV coinfection, and its clinical implications remain unclear. We review the literature and report our recent experience with a 44-year-old man with HBV/HIV coinfection who developed metastatic hepatocellular carcinoma despite quiescent HBV and HIV disease courses. Highly active antiretroviral therapy has revolutionized HIV disease. As a result, morbidity and mortality from other underlying chronic, non-HIV-related diseases, such as the HBV infection and hepatocellular carcinoma reported here, will likely continue to increase in the HIV-infected patient population.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Centers for Disease Control and Prevention. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination—Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991; 40( RR-13): 1–25.
 
2. Befeler AS, Di Bisceglie AM. Hepatitis B. Infect Dis Clin North Am 2000; 14: 617–632.
 
3. Coleman PJ, McQuillan GM, Moyer LA, et al. Incidence of hepatitis B virus infection in the United States, 1976–1994: estimates from the National Health and Nutrition Examination Surveys. J Infect Dis 1998; 178: 954–959.
 
4. Hadler SC, Judson FN, O’Malley PM, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991; 163: 454–459.
 
5. Scharschmidt BF, Held MJ, Hollander HH, et al. Hepatitis B in patients with HIV infection: relationship to AIDS and patient survival. Ann Intern Med 1992; 117: 837–838.
 
6. Ockenga J, Tillmann HL, Trautwein C, et al. Hepatitis B and C in HIV-infected patients: prevalence and prognostic value. J Hepatol 1997; 27: 18–24.
 
7. Eskild A, Magnus P, Petersen G, et al. Hepatitis B antibodies in HIV-infected homosexual men are associated with more rapid progression to AIDS. AIDS 1992; 6: 571–574.
 
8. McDonald MI, Hamilton JD, Durack DT. Hepatitis B surface antigen could harbour the infective agent of AIDS. Lancet 1983; 2: 882–884.
 
9. Gilson RJ, Hawkins AE, Beecham MR, et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS 1997; 11: 597–606.
 
10. Alka S, Hemlata D, Vaishali C, et al. Hepatitis B virus surface (S) transactivator with DNA-binding properties. J Med Virol 2000; 61: 1–10.
 
11. Beasley RP, Hwang LY, Lin CC, et al. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,707 men in Taiwan. Lancet 1981; 2: 1129–1133.
 
12. Garcia-Samaniego J, Rodriguez M, Berenguer J, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 179–183.
 
13. Brockmeyer N, Barthel B. Clinical manifestations and therapies of AIDS associated tumors. Eur J Med Res 1998; 3: 127–147.
 
14. Holmberg SD. Possible cofactors for the development of AIDS-related neoplasms. Cancer Detect Prev 1990; 14: 331–336.
 
15. Schulz TF, Boshoff CH, Weiss RA. HIV infection and neoplasia. Lancet 1996; 348: 587–591.
 
16. Smukler AJ, Ratner L. Hepatitis viruses and hepatocellular carcinoma in HIV-infected patients. Curr Opin Oncol 2002; 14: 538–542.
 
17. Martín-Carbonero L, Soriano V, Valencia E, et al. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001; 17: 1467–1471.
 
18. Cheney CP, Chopra S, Graham C. Hepatitis C. Infect Dis Clin North Am 2000; 14: 633–667.
 
19. Chiaramonte M, Stroffolini T, Vian A, et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999; 85: 2132–2137.
 
20. Bonacini M, Puoti M. Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues. Arch Intern Med 2000; 160: 3365–3373.
 
21. Housset C, Pol S, Carnot F, et al. Interactions between human immunodeficiency virus-1, hepatitis delta virus and hepatitis B virus infections in 260 chronic carriers of hepatitis B virus. Hepatology 1992; 15: 578–583.
 
22. Colin JF, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29: 1306–1310.
 
23. Bodsworth N, Donovan B, Nightingale BN. The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis 1989; 160: 577–582.
 
24. Di Bisceglie AM, Carithers RL Jr, Gores GJ. Hepatocellular carcinoma. Hepatology 1998; 28: 1161–1165.
 
25. Lok AS, McMahon BJ. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Chronic hepatitis B. Hepatology 2001; 34: 1225–1241.
 
26. Tanaka T, Imamura A, Masuda G, et al. A case of hepatocellular carcinoma in HIV-infected patient. Hepatogastroenterology 1996; 43: 1067–1072.
 
27. Cromlish JA. Hepatitis B virus-induced hepatocellular carcinoma: possible roles for HBx. Trends Microbiol 1996; 4: 270–274.
 
28. Gomez-Gonzalo M, Carretero M, Rullas J, et al. The hepatitis B virus X protein induces HIV-1 replication and transcription in synergy with T-cell activation signals: functional roles of NF-kappaB/NF-AT and SP1-binding sites in the HIV-1 long terminal repeat promoter. J Biol Chem 2001; 276: 35435–35443.
 
29. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000—Summary of a workshop. Gastroenterology 2001; 120: 1828–1853.
 
30. Twu JS, Chu K, Robinson WS. Hepatitis B virus X gene activates kappa B-like enhancer sequences in the long terminal repeat of human immunodeficiency virus 1. Proc Natl Acad Sci U S A 1989; 86: 5168–5172.
 
31. Barak O, Aronheim A, Shaul Y. HBV X protein targets HIV Tat-binding protein 1. Virology 2001; 283: 110–120.
 
32. Vento S, di Perri G, Luzzati R, et al. Clinical reactivation of hepatitis B in anti-HBs-positive patients with AIDS. Lancet 1989; 1: 332–333. (letter)
 
33. Lazizi Y, Grangeot-Keros L, Delfraissy JF, et al. Reappearance of hepatitis B virus in immune patients infected with the human immunodeficiency virus type 1. J Infect Dis 1988; 158: 666–667(letter).
 
34. Altfeld M, Rockstroh JK, Addo M, et al. Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal. J Hepatol 1998; 29: 306–309.
 
35. Perrillo RP. Acute flares in chronic hepatitis B: The natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120: 1009–1022.
 
36. Mai AL, Yim C, O’Rourke K, et al. The interaction of human immunodeficiency virus infection and hepatitis B virus infection in infected homosexual men. J Clin Gastroenterol 1996; 22: 299–304.
 
37. Carr A, Cooper DA. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 1997; 349: 995–996(letter).